J Korean Neurosurg Soc.  1998 Mar;27(3):363-368.

Prognostic Factors for Shunting in Medulloblastoma Combined with Hydrocephalus

Affiliations
  • 1Department of Neurosurgery, Medical College, Catholic University, Seoul, Korea.

Abstract

The majority of patients with medulloblastoma present with hydrocephalus. It has been reported, however, that not all medulloblastoma patients will continue to have hydrocephalus after the tumor is resected, and in fact, only selected patients need permanent shunts. To retrospectively identify the prognostic factors indicating this requirement, we analysed several charateristics in patients without preoperative shunts suffering from medulloblastoma combined with hydrocephalus. We studied 32 patients and divided them into two groups: those requiring shunts within 4 weeks of surgery, and those not shunted. Nine patients(28%) required a permanent shunt. We found that these patients were younger(4.8+/-4.3 vs. 9.6+/-7.4 years; p<0.05), had more extensive tumors (Chang's stage T2 vs. T3; p<0.050), and that postoperatively, some tumor remained(p<0.05). However, with regard to gender, symptoms of increasedintracranial pressure(ICP), the duration of these symptoms, positive cerebrospinal fluid(CSF) cytology, perioperative external ventricular drainage, and degree of preoperative hydrocephalus, there were no differences between the groups. It was thus concluded that younger patients with extensive preoperative tumors and tumors remaining after surgery may benefit from postoperative CSF diversion. It was thought that patients not fitting the above criteria can probably be managed with perioperative corticosteroids alone.

Keyword

Medulloblastoma; Hydrocephalus; Prognostic factors; Permanent shunt

MeSH Terms

Adrenal Cortex Hormones
Drainage
Humans
Hydrocephalus*
Medulloblastoma*
Retrospective Studies
Adrenal Cortex Hormones
Full Text Links
  • JKNS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr